✨ Free AI Report
Gedeon Richter Plc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Gedeon Richter Plc.
Company Research

Gedeon Richter Plc.: Business Overview, Financials & Competitive Analysis

Gedeon Richter Plc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Diversified specialty pharma platform with regional dominance and meaningful international expansion capturing secular growth in biosimilars and specialty medicines. Regional pharmaceutical leader with significant R&D capabilities, established market position across 100+ countries, and strategic focus on high-value therapeutic areas (oncology, neuroscience, women's health). Strengths include biosimilar pipeline development and.

What is Gedeon Richter Plc.'s industry? Gedeon Richter Plc. (gedeonrichter.com) operates in Pharmaceutical and Biotechnology. AskCyborg classifies Gedeon Richter Plc. under Pharmaceutical and Biotechnology in its company registry.

Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest and the largest pharmaceutical company in Central and Eastern Europe. An innovation-driven specialty p...

7/ 10Strong

Cyborg Score thesis

Diversified specialty pharma platform with regional dominance and meaningful international expansion capturing secular growth in...

Read the full analyst-debate transcript →
Industry Pharmaceutical and Biotechnology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 28, 2026
AI-Verified Research
30+ Page Report

Get the Latest Gedeon Richter Plc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Gedeon Richter Plc.

AskCyborg analysts argue the bull and bear cases for Gedeon Richter Plc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Gedeon Richter Plc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Gedeon Richter Plc. Overview

Pro stress-test →

Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest and the largest pharmaceutical company in Central and Eastern Europe. An innovation-driven specialty pharmaceutical company with vertically integrated activities involving pharmaceutical manufacturing, research and development, sales and marketing.

Strategic Profile

Pro stress-test →

The company sells products for neuroscience, oncology, women's health and cardiovascular therapeutic areas and is active in biosimilar product development. Richter has the largest R&D unit in Central and Eastern Europe and operations in over 100 countries.

Competitive Landscape

Pro stress-test →

Richter competes with larger multinational pharmaceutical companies like Novartis, Roche, and AbbVie in oncology and neuroscience segments. Regional competition includes Polish and Czech pharmaceutical manufacturers. Differentiation stems from R&D leadership in CEE region, biosimilar capabilities, and established supply chains throughout Eastern Europe.

Industry Context

Gedeon Richter Plc. operates in Pharmaceutical and Biotechnology.

Key facts

Founded: 1901 · Headquarters: Budapest, Hungary · Employees: Not available in current data · Revenue: Not available in current data · Market cap: $6.6B (2018)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Gedeon Richter Plc..

  • Largest pharmaceutical company in Central and Eastern Europe with presence in UK, Western Europe, China, North America and Latin America
  • Cariprazine (Reagila) atypical antipsychotic awarded Medicine of the Year 2019 by Hungarian Society for Experimental and Clinical Pharmacology
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2024AbbVie collaboration for neuropsychiatric disease drug development
  • 2022Strategic research collaboration with FimmCyte AG announced
  • +2 moreTrack every material event for Gedeon Richter Plc. as it happens. Explore monitoring →
Get alerted when Gedeon Richter Plc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Oncology and Neuroscience TherapeuticsGlobal pharmaceutical leader→Specialty MedicinesMultinational pharmaceutical conglomerate→Biosimilar ProductsBiosimilar and generic specialist→

Compare Gedeon Richter Plc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Gedeon Richter Plc. operates in Pharmaceutical and Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical and Biotechnology research →
NEW · MCP server

Ask your AI assistant about Gedeon Richter Plc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Gedeon Richter Plc. and its top competitor on Cyborg Score”
“What did Gedeon Richter Plc. do this quarter?”
“Is Gedeon Richter Plc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Gedeon Richter Plc. do?+
Gedeon Richter Plc. is a European multinational pharmaceutical and biotechnology company headquartered in Budapest and the largest pharmaceutical company in Central and Eastern Europe. An innovation-driven specialty p...
What is Gedeon Richter Plc.'s Cyborg Score?+
Gedeon Richter Plc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Gedeon Richter Plc.'s main competitors?+
Named competitors include Oncology and Neuroscience Therapeutics, Specialty Medicines, Biosimilar Products. The full competitive landscape is in the AskCyborg report.
How can I get the full Gedeon Richter Plc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Gedeon Richter Plc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Gedeon Richter Plc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceutical and Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7GSK plc7Pfizer Inc.